A Study of the Safety, Immunopharmacodynamics and Anti-tumor Activity of Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Adenocarcinoma
Phase of Trial: Phase I/II
Latest Information Update: 22 Jul 2017
At a glance
- Drugs Ibrutinib (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Pharmacokinetics
- 17 Jul 2017 Planned End Date changed from 1 Mar 2018 to 1 Jun 2018.
- 17 Jul 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018.
- 19 Nov 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.